Affirm stock is sizzling Friday after the BNPL firm handily beat earnings and revenue estimates in its most recent quarter.

BofA analyst Tim Anderson raised the firm’s price target on Eli Lilly (LLY) to $1,000 from $997 and keeps a Buy rating on the shares after ...

In a report released today, Geoff Meacham from Citi maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares ...

U.S. markets closed mixed with S&P 500 and Nasdaq gaining, while Dow slipped. Economic data exceeded expectations, while commodities and futures showed mixed results. Markets await key reports and ...

Wall Street drifted through mixed trading Thursday as rising fashion and cigarette stocks worked against drops for Ford Motor and Qualcomm. The S&P 500 rose 0.4% following healthy gains for stock ...

Wall Street drifted through mixed trading Thursday as rising fashion and cigarette stocks worked against drops for Ford Motor ...

U.S. stock markets closed mixed on Thursday after a choppy session. Market participants waited for the key labor market data of January to be released on Friday. Moreover, strong fourth-quarter 2024 ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Health-care companies rose after strong earnings from one obesity-drug maker. Eli Lilly shares rose after it reiterated its forecast for 32% 2025 revenue growth, amid rising demand for its Zepbound ...

We expect Lilly to continue to grow faster than the market, and model 60% 2025 Lilly GLP-1 sales growth. Lilly gained 5 points in US prescription share in 2024, and Zepbound’s 56% share of new ...